Cencora, Inc.
Explore Cencora
Core profile pages, annual revenue records, and related research hubs for this company.
Leadership History
4 leaders · Full leadership timeline
Cencora buys and distributes pharmaceuticals, specialty drugs, animal health products, and related healthcare supplies while also providing commercialization, logistics, and provider services through U.S. and international platforms.
Cencora makes money primarily through high-volume pharmaceutical wholesale distribution. It also earns revenue from specialty distribution, provider services, international distribution, biopharma logistics, commercialization services, and animal-health distribution.
President and Chief Executive Officer
Mauch leads Cencora's pharmaceutical distribution, specialty, and international healthcare solutions strategy.
Former Chief Executive Officer
Collis led AmerisourceBergen through specialty expansion, international acquisitions, the Cencora rebrand, and the leadership transition to Robert P. Mauch.
Executive Vice President and Chief Financial Officer
Cleary oversees financial reporting, capital allocation, and working-capital discipline in a high-volume distribution business.
Chair of the Board
Durcan chairs Cencora's board as the company scales its healthcare-solutions and specialty-services platform.
Cencora's main challenges are the economics and oversight burden of pharmaceutical distribution: thin margins, large customer concentration, controlled-substance compliance, reimbursement pressure, cybersecurity risk, and the continuing cash cost of legal settlements.
Robert P. Mauch is President and Chief Executive Officer of Cencora.
Steven H. Collis led AmerisourceBergen/Cencora before retiring from the CEO role in 2024.
The Cencora name was adopted in 2023 to reflect a broader global healthcare-services identity.
Leadership decisions shape distribution contracts, specialty expansion, acquisition priorities, and compliance discipline.